In contrast, overexpression of BRG1 has been observed in most human breast cancer tumors, and BRG1 knockdown has been shown to sensitize triple negative breast cancer cells to chemotherapy drugs [282]. Here, SMARCA4 is linked to triple-negative breast carcinoma.